GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Circulation, Ovid Technologies (Wolters Kluwer Health), Vol. 129, No. suppl_1 ( 2014-03-25)
    Abstract: Introduction: Dietary fatty acids have a role in many physiological mechanisms that influence cardiovascular health. An emerging body of evidence suggests that dietary fats may interact with genetic variants in regulating tissue levels of fatty acids, thus impacting disease risk. Epigenetic changes such as DNA methylation are a promising mechanism underlying such interactions. However, no studies to date have investigated the relationship between DNA methylation and tissue fatty acids at the genome-wide level. Methods: We have performed the first epigenome-wide association study (EWAS) of erythrocyte concentrations of polyunsaturated, monounsaturated, saturated, and trans fatty acids in 958 participants of the Genetics of Diet and Lipid Lowering Drugs Network (GOLDN). We assayed the methylation status of approximately 450,000 CpG sites in CD4+ T-cells. To investigate the associations between methylation of each CpG site and red blood cell fatty acids, we fit linear mixed models adjusted for age, sex, cell purity, and family structure. Results: The strongest association was observed between the methylation status of a CpG site in PDE4D, previously linked to systemic inflammation and stroke, and red blood cell trans fatty acids (P=4x10-7). In the analysis of polyunsaturated fatty acids, we found inverse associations with the methylation status of two CpG sites in BRSK2 (P=9x10-6 and P=1x10-5 respectively), as well as with a CpG site located in a “gene desert” on chromosome 14 proximally to VRK1 (P=5x10-7). BRSK2 encodes a kinase previously shown to control epigenetic programs that determine T-cell function. The top hits for monounsaturated and saturated fatty acids were located in ATL2 (P=1x10-6) and FGD2 (P=1x10-5), respectively. Conclusions: We present preliminary evidence of cross-sectional association between the methylation status of several biologically relevant genomic regions and erythrocyte concentrations of polyunsaturated, trans, monounsaturated, and saturated fatty acids. Upon successful validation, these findings further current understanding of gene-fatty acid interactions in human health and disease.
    Type of Medium: Online Resource
    ISSN: 0009-7322 , 1524-4539
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2014
    detail.hit.zdb_id: 1466401-X
    detail.hit.zdb_id: 80099-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Arteriosclerosis, Thrombosis, and Vascular Biology, Ovid Technologies (Wolters Kluwer Health), Vol. 32, No. suppl_1 ( 2012-05)
    Abstract: Introduction: Despite the widespread use of fibrates in treatment of dyslipidemia, the observed response is highly heterogeneous, suggesting a role for genetic determinants. Whether replicated variants associated with blood lipids identified by genome wide association studies (GWAS) are also associated with lipid response to fenofibrate is unknown. Objectives: To test if 95 genome-wide significant loci identified in a recent meta-analysis of blood lipids are associated with changes in high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), non-HDL-C, and triglycerides (TG) following 3 weeks of therapy with 160 mg of micronized fenofibrate. Methods: Using data from 861 European American Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) participants, we fit mixed linear models with baseline blood lipids and the post-to-pre fenofibrate treatment ratio of blood lipid levels as outcomes, the corresponding genetic markers from the published meta-analysis as predictors, and age, sex, pedigree, and ancestry as assessed by principal components as covariates. A Bonferroni correction was applied to adjust for multiple comparisons. Least square means were used to report the direction of fenofibrate-induced changes by genotype. Results: We observed statistically significant associations between rs964184 , a variant near the APOA1 gene, and baseline HDL-C (P 〈 0.0001) and baseline TG (P 〈 0.0001), as well as with diminished response to fenofibrate as evidenced by a smaller increase in HDL-C (P 〈 0.0001) and a smaller decrease in TG (P=0.0001) per each copy of the variant allele. Additionally, we report suggestive associations of rs3764261 locus in the CETP gene and the rs10401969 locus in the CILP2 gene with decreased fenofibrate response as measured by changes in LDL-C (P=0.0003 and 0.02, respectively) and non-HDL-C (P=0.004 and 0.005, respectively). Conclusions: We have identified several novel biologically relevant loci associated with baseline blood lipids and fenofibrate-induced changes in blood lipids.
    Type of Medium: Online Resource
    ISSN: 1079-5642 , 1524-4636
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2012
    detail.hit.zdb_id: 1221433-4
    detail.hit.zdb_id: 1494427-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Circulation, Ovid Technologies (Wolters Kluwer Health), Vol. 125, No. suppl_10 ( 2012-03-13)
    Abstract: Shifts in lipoprotein diameter occur in insulin resistant (IR) patients - a known risk factor for cardiovascular disease. Fenofibrate modulates lipoprotein markers in a manner which is expected to reduce the risk of adverse cardiovascular events. However inter-individual variability in response to fenofibrate is very high. We aimed to examine phenotype-variant associations with shifts in lipoprotein diameter, for each of the three fractions of lipoprotein, in response to a three-week fenofibrate trial. Participants formed the general population sample from that Genetics of Lipid Lowering Drugs and Diet Network (n=817; mean age of 48.8 ± 16.2 y). Very-low, low- and high- density lipoprotein diameters were measured using NMR spectroscopy before and after a 3-week fenofibrate treatment (160mg/day). Lipoprotein diameter change, for each fraction, was calculated using growth curve models which modeled compliance with the fenofibrate protocol. Associations between single nucleotide polymorphisms on the Affymetrix 6.0 chip and lipoprotein diameter change were assessed using mixed linear models, adjusted for age, sex, study center, and family. A Bonferroni correction for multiple testing was used, with genome wide levels of significance set at P 〈 1.97*10 -08 . Given power problems inherent in using change scores, suggestive levels of significance were set at P 〈 1.97 * 10 -06 where there were more than five hits at this level within a 500kb region. The AHCLY2 ( P 〈 3.95*10 -08 ) gene was significantly associated with very-low density lipoprotein diameter. 14 genes reached suggestive levels of significance ( Table 1 ). We conclude that genes previously associated with inflammation ( LPAR1 , GRP110 ) and insulin ( PION , EIF2AK3 , CHRM3 , WNT ) may mediate lipoprotein diameter response to fenofibrate. Upon replication in clinical populations, this may help understand the co-occurrence of IR, inflammation and cardiovascular disease as well the mechanisms of action and therapeutic potential of fenofibrate's role in patients with IR. Table 1 Significant, and suggestive genotype-phenotype associations from a genome-wide study investigating genetic associations with VLDL, LDL and HDL diameter changes in response to fenofibrate Gene Response phenotype 1 P-value 2 Previous associations 3 AHCLY2 VLDL 3.95*10 -09 Produces an enzyme necessary for methylation DOCK4 VLDL 1.39*10 -07 - PPARG HDL 2.87*10 -07 Increases expression of ABCA1; target of thiazolidinediones used to treat insulin resistance ACCSL HDL 5.18*10 -07 - TFAP2A HDL 5.26*10 -07 cardiomyopathy PPTC7 HDL 6.40*10 -07 - NSUN3 HDL 6.45*10 -07 - RPLP1 HDL 6.47*10 -07 - ORK2 HDL 9.10*10 -07 Olfactory receptor G-protein coupled gene LPAR1 HDL 9.10*10 -07 inflammation, adipogenesis GPR110 VLDL 2.97*10 -06 G-protein coupled gene, inflammation EIF2AK3 VLDL 7.02*10 -06 insulin secretion, type 2 diabetes CHRM3 HDL 3.63*10 -06 insulin secretion, type 2 diabetes PLD1 VLDL 6.75*10 -06 insulin secretion and lipid droplet formation TINK VLDL 6.75*10 -06 wnt signaling, type 2 diabetes Abbreviations: VLDL: very-low density lipoprotein; LDL: low-density lipoprotein, HDL: High density lipoprotein 1 Diameter change 2 Smallest p-value for a single phenotype-variant association within the gene 3 PubMed searches for the genes where within the gene single nucleotide polymorphisms were associated at ( P 〈 1.97 * 10 -06 ).
    Type of Medium: Online Resource
    ISSN: 0009-7322 , 1524-4539
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2012
    detail.hit.zdb_id: 1466401-X
    detail.hit.zdb_id: 80099-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Circulation, Ovid Technologies (Wolters Kluwer Health), Vol. 127, No. suppl_12 ( 2013-03-26)
    Abstract: Introduction: Chronic systemic inflammation is a complex trait characterized by moderate to high heritability and important implications for cardiovascular health. Previously identified genetic polymorphisms explain only a modest fraction of variability in circulating inflammatory marker concentrations. Hypothesis: We hypothesized that variation in DNA methylation patterns contributes to the missing heritability of inflammatory traits, and that such associations may in turn be influenced by environmental factors (smoking, alcohol, and obesity) as well as common genetic variants. Methods: Using data from the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN, n= 593), we assayed the methylation status of approximately 450,000 sites across the genome and measured serum concentrations of high-sensitivity C-reactive protein (hsCRP), soluble interleukin-2 receptor alpha (sIL2Ra), interleukin-6 (IL6), tumor necrosis factor alpha (TNFa), and monocyte chemoattractant protein 1 (MCP1). To investigate and validate the associations between DNA methylation patterns and systemic inflammation, we split the GOLDN data set into discovery (n= 451) and replication (n= 142) data sets. During the discovery stage, we modeled continuous methylation scores at each site on inflammatory markers, adjusted for age, sex, study site, and T-cell purity as fixed effects and family structure as a random effect. Results: After correcting for multiple comparisons, the strongest signal was obtained from an intergenic CpG island on chromosome 20 and levels of hsCRP (P=5×10-10) and sILR2a (P=6×10-6). Our findings are consistent with previous linkage studies that have identified a quantitative trait locus for inflammation in an adjacent region of chromosome 20. Moreover, the association with sIL2Ra but not hsCRP was observed in replication analyses (P=0.008). Models adjusting for current smoking status, alcohol consumption, or body mass index did not appreciably change the estimates of association. Finally, we performed a genome-wide analysis to identify quantitative trait loci for methylation of the CpG site on chromosome 20. We found a genome-wide significant (P=3×10×-8) association with rs11223480 on chromosome 11 in OPCML, which encodes a tumor suppressor, and suggestive (P 〈 4×10-6) associations with a cluster of 9 variants located on chromosome 20 in MACROD2, a gene previously reported to be associated with systemic inflammation. Conclusions: We have conducted the first integrated study of epigenetic variation, genotype, and circulating inflammatory marker concentrations. In conclusion, our findings suggest that differential methylation of an intergenic region on chromosome 20, likely in conjunction with the underlying genotype, is associated with systemic inflammation and merits further evaluation as a cardiovascular risk factor.
    Type of Medium: Online Resource
    ISSN: 0009-7322 , 1524-4539
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2013
    detail.hit.zdb_id: 1466401-X
    detail.hit.zdb_id: 80099-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...